This EU-based key opinion leader (KOL) discusses key topics in the wet AMD field. He opines on the current trends in biologics prescription among retina specialists, patient pathways in receiving treatment and addresses the impact of governing bodies on choosing treatment plans for the patients in the region. The KOL also adds the impact of biosimilars and potential impact of newer therapies focusing on Eylea HD. He also opines on the novel delivery routes being investigated and the innovations in pipeline therapies.

This interview was conducted on January 17, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.  

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.